Journal
NATURE
Volume 586, Issue 7830, Pages 567-+Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41586-020-2622-0
Keywords
-
Categories
Funding
- Intramural Research Program of the VRC
- Division of Intramural Research, NIAID, NIH
- NIH NIAID [R01-AI127521, T32-AI007151]
- NIH [AI149644, AI100625, HHSN261200800001E, HHSN272201700036I, 75N93019F00132, 5494549]
- Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority [75A50120C00034]
- Undergraduate Scholarship Program, Office of Intramural Training and Education, Office of the Director, NIH
- Burroughs Wellcome Fund Postdoctoral Enrichment Program Award
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI005125, ZIAAI005152] Funding Source: NIH RePORTER
Ask authors/readers for more resources
A vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed to control the coronavirus disease 2019 (COVID-19) global pandemic. Structural studies have led to the development of mutations that stabilize Betacoronavirus spike proteins in the prefusion state, improving their expression and increasing immunogenicity(1). This principle has been applied to design mRNA-1273, an mRNA vaccine that encodes a SARS-CoV-2 spike protein that is stabilized in the prefusion conformation. Here we show that mRNA-1273 induces potent neutralizing antibody responses to both wild-type (D614) and D614G mutant(2) SARS-CoV-2 as well as CD8(+) T cell responses, and protects against SARS-CoV-2 infection in the lungs and noses of mice without evidence of immunopathology. mRNA-1273 is currently in a phase III trial to evaluate its efficacy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
